Concurrently, assessing the ubiquitination levels of ACSL4 in prostate cancer cells, we ascertained that SKP2’s overexpression markedly amplified ACSL4 ubiquitination in a dose-correlated manner (Fig. 4H). Here, SKP2 is linked to prostate cancer.